Search
aTyr Pharma Ord Shs
LIFEAdd to Watchlist
19.590USD
+0.230+1.19%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.23BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of aTyr Pharma Ord Shs is 8.89, ranking 37 out of 387 in the Biotechnology & Medical Research industry.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
28.286
Target Price
+49.66%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
aTyr Pharma Ord Shs
LIFE
9
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is aTyr Pharma Ord Shs's expected revenue for the next quarter?
aTyr Pharma Ord Shs's expected revenue is 117.14M.
How have aTyr Pharma Ord ShsLIFE's recent earnings per share performed?
The market expectation was USD -3.57, while aTyr Pharma Ord ShsLIFE's earnings per share (EPS) for the previous quarter was USD 0.39. EPS for the next quarter is expected at USD 0.24.
What is the analyst rating for aTyr Pharma Ord Shs?
Based on the ratings of aTyr Pharma Ord Shs's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.